Traders should anticipate near-term downward pressure on the stock due to dilution; monitor for insider selling or short interest changes. The capital raise extends the runway for SAB-142 development, but lack of near-term catalysts may limit upside until clinical data releases.
Price Chart
Executive Summary
SAB Biotherapeutics (SABS) announced the pricing of a public offering, selling 19.3 million shares at $3.85 and pre-funded warrants for 2.8 million shares at $3.8499, raising approximately $85 million in gross proceeds. The funds will primarily support clinical development of its lead candidate, SAB-142, for type 1 diabetes. The offering includes a 30-day underwriter option to purchase up to an additional 3.3 million shares.
Key Financial Metrics
Key Facts
- SAB Biotherapeutics is raising approximately $85 million through a public offering of common stock and pre-funded warrants.
- 19,324,677 shares priced at $3.85 per share; pre-funded warrants for 2,753,246 shares priced at $3.8499.
- Underwriters have a 30-day option to purchase up to 3,311,688 additional shares.
- Proceeds will fund development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes.
- The offering is expected to close on or about March 19, 2026, subject to customary conditions.
Financial Impact
$85 million gross proceeds, with significant dilution from ~19.3M new shares and ~2.8M pre-funded warrants; underwriters may add ~3.3M more shares.
Risk Factors
- Significant shareholder dilution from issuance of over 22 million shares (including warrants and potential over-allotment).
- Biotech clinical-stage risk: SAB-142 is still in Phase 2b with no guarantee of success.
- Market conditions could delay or alter the final closing terms, though pricing is already set.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257861 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 7, 2026 12w ago | 8-K | $3.90 $3.17 | ▼ −18.72% | ▼ −20.71% | $2.98 (−23.59%) |
May 29, 2026 18w ago | Press Release | $3.60 $3.62 | ▲ +0.56% | ▼ −0.63% | $2.98 (−17.22%) |
May 12, 2026 20w ago | Press Release | $3.62 $3.85 | ▼ −6.35% | ▼ −1.97% | $2.98 (+17.68%) |
Mar 19, 2026 28w ago | Press Release | $3.75 $3.90 | ▲ +4.00% | ▼ −10.42% | $2.98 (−20.53%) |
Mar 19, 2026 28w ago | 8-K | $3.78 $3.90 | ▼ −3.17% | ▲ +11.17% | $2.98 (+21.16%) |
Mar 18, 2026 28w ago | Press Release | $3.70 $3.38 | ▲ +8.65% | ▲ +20.17% | $2.98 (+19.46%) |
Mar 17, 2026 28w ago | Press Release | $3.70 $3.38 | ▲ +8.65% | ▲ +20.17% | $2.98 (+19.46%) |
Mar 10, 2026 29w ago | Press Release | $4.10 $3.36 | ▼ −18.05% | ▼ −29.73% | $2.98 (−27.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access